Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 

7 Binary Options

 

Enter Stock Symbol:  

Eleven Bio Inc (EBIO)

1.28 +0.01 (+0.79%)

8/16/2017  1:05pm

Open:

1.27

Pre. Close:

1.27

High:

1.28

Low:

1.26

Volume:

44,603

Market Cap:

19.70M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

1.4 - 1.54

1.54 - 1.66

Low:

1.19 - 1.21

1.21 - 1.23

Close:

1.22 - 1.3

1.3 - 1.37

Technical analysis  (as of: 2017-08-16 1:09:17 PM)

Overall:

      

Stoxline posted a SELL today, same as yesterday. This stock seems to continue bearish move. So you may continue to hold short positions or sell your long positions. You are relatively safe to short or sell now, downward move is expected.

Target:

Six months: 1.77     One year: 1.96

Support:

Support1: 1.26    Support2: 1.05

Resistance:

Resistance1: 1.52    Resistance2: 1.68

Pivot:

1.41

Moving Averages:

MA(5): 1.33     MA(20): 1.44

MA(100): 1.64     MA(250): 2.17

MACD:

MACD(12,26): -0.06     Signal(12,26,9): -0.04

%K %D:

%K(14,3): 7.01     %D(3): 13.67

RSI:

RSI(14): 35.28

52-Week:

High: 5.40  Low: 1.26  Change(%): -74.3

Average Vol(K):

3-Month: 20753  10-Days 5272

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
EBIO has closed above bottom band by 8.8%. Bollinger Bands are 1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Mon, 14 Aug 2017 11:21:23 GMT
BRIEF-Eleven Biotherapeutics Q2 loss per share $0.30

Mon, 14 Aug 2017 10:52:30 GMT
Eleven Biotherapeutics Reports Second Quarter 2017 Financial Results

Thu, 29 Dec 2016 16:30:00 GMT
Eleven Bio: Is It Cheap?

Mon, 16 May 2016 13:41:40 GMT
Eleven Biotherapeutics: A Buyout Likely Coming

Wed, 21 Sep 2016 17:04:28 GMT
Eleven Biotherapeutics buys Canadian company

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Bio Therapeutic Drugs

Shares Out. (M)

24.70

Shares Float (M)

7.80

% Held by Insiders

12.73

% Held by Institutions

73.60

Shares Short (K)

1670

Shares Short Prior Month (K)

1610

Stock Financials

EPS

0.150

EPS Est. Current Year

-1.750

EPS Est. Next Year

-1.850

EPS Est. Next Quarter

Forward EPS

1.#IO

Book Value (p.s.)

1.330

PEG Ratio

Profit Margin

11.28

Operating Margin

26.69

Return on Assets (ttm)

8.9

Return on Equity (ttm)

15.2

Qtrly Rev. Growth

85.6

Gross Profit (p.s.)

1.214

Sales Per Share

EBITDA (p.s.)

0.334

Qtrly Earnings Growth

Operating Cash Flow (M)

5.98

Levered Free Cash Flow (M)

9.53

FoxReading.com

Valuation

P/E

8.53

P/E Growth Ratio

0.01

P/BV

0.96

P/S

23419258.00

P/CF

5.29

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.